Juvenile Idiopathic Arthritis News and Research

RSS

Juvenile idiopathic arthritis (JIA) is the name given to a group of conditions characterized by joint inflammation or arthritis, occurring first before the age of 16.

Experts look for ways to standardize treatments for pediatric rheumatic diseases

Pediatric rheumatic diseases are a varied group of rare diseases including juvenile forms of arthritis, lupus, fibromyalgia, and other conditions.

15 Jan 2018

Internet-based educational program improves health-related quality of life for teens with JIA

An internet-based health education and self-management program that offers monthly calls with health coaches improved health-related quality of life for participating teens with juvenile idiopathic arthritis, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.

6 Nov 2017

Juvenile idiopathic arthritis affects more than 300,000 children in the U.S.

When most people think of arthritis, they picture the knobby knuckles, inflamed joints or aching back of an older person. But more than 300,000 children in the U.S. suffer from chronic juvenile idiopathic arthritis (JIA), which has more to do with joint inflammation than wear and tear on cartilage and bone.

12 Oct 2017

Scientists uncover new group of Treg cells and DNA features linked to juvenile idiopathic arthritis

A team of scientists and doctors from the SingHealth Duke-NUS Academic Medical Centre has uncovered a new group of regulatory T (Treg) cells and DNA features associated with juvenile idiopathic arthritis (JIA), the most common form of arthritis among children under the age of 16.

14 Jul 2017

Reintroduction of PATA could improve patient access to life-saving drugs

The American College of Rheumatology today applauded the leadership of Rep. David McKinley and Rep. G.K. Butterfield in reintroducing H.R. 2999, the Patients' Access to Treatment Act.

24 Jun 2017

New guidelines for anti-rheumatic drug management in patients having joint replacement surgery

In the first such collaboration of its kind, an expert panel of rheumatologists and orthopedic surgeons has developed guidelines for the perioperative management of anti-rheumatic medication in patients undergoing total hip or knee replacement.

16 Jun 2017

ACR, AAHKS release new guideline to reduce joint infections after total hip and knee replacements

According to a new guideline released by the American College of Rheumatology and American Association of Hip and Knee Surgeons, the risk of joint infection resulting from total hip and knee replacements can be reduced with careful management of anti-rheumatic medications during the perioperative process.

16 Jun 2017

FOI technique found to be effective in detecting joint inflammation in children

The results of a study presented today at the Annual European Congress of Rheumatology 2017 have confirmed that Fluorescence Optical Imaging, a technique used to visualize inflammation in arthritic joints, is as effective as ultrasound with Power Doppler (US / PD) at monitoring response to treatment in juvenile idiopathic arthritis.

14 Jun 2017

Clinical trial discovers drug combination that could help children with arthritis

A clinical trial funded by Arthritis Research UK and the National Institute for Health Research led by professors from the Universities of Liverpool and Bristol has discovered a drug combination that could help thousands of children with arthritis.

27 Apr 2017

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis announced today that the US Food and Drug Administration has granted three simultaneous approvals for the expanded use of Ilaris (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes.

24 Sep 2016

FDA approves new biosimilar for multiple inflammatory diseases

The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.

23 Sep 2016

Report: Britons at risk of long-term disability, reduced life expectancy due to delays in treatment services

Up to a million Britons are at risk of preventable, long-term disability and reduced life expectancy due to delays in referrals to specialist advice and treatment services, according to the most comprehensive audit of rheumatology services carried out across England and Wales.

25 Jul 2016

TTR protein causes autoimmune reaction in joints of juvenile idiopathic arthritis patients

Juvenile idiopathic arthritis, or JIA, is the most common form of childhood arthritis. It appears to be an autoimmune disease, caused by antibodies attacking certain proteins in a person's own tissue. But no "autoantigens" -- the proteins triggering an immune attack -- have been linked to JIA.

27 Feb 2016

Aggregated forms of transthyretin can trigger JIA development

Juvenile idiopathic arthritis (JIA) is a the most common form of arthritis in children and affects approximately 50,000 individuals in the United States alone. Previous research suggested that autoimmune responses cause JIA, but the specific antigens that are responsible for driving autoimmunity have not been identified.

26 Feb 2016

People with viral infections and identical gene mutations may be prone to hyperinflammatory disorder

A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a study in The Journal of Infectious Diseases.

25 Nov 2015

Scientists calculate precise measurements of heritability in nine pediatric-onset autoimmune diseases

Scientists have calculated more precise measurements of heritability--the influence of underlying genes--in nine autoimmune diseases that begin in childhood. The research may strengthen researchers' abilities to better predict a child's risk for associated autoimmune diseases.

9 Oct 2015

Cleveland Clinic Children's to host second annual Pediatric Innovation Summit

Cleveland Clinic Children's will host its second annual Pediatric Innovation Summit June 11 to 13, 2015, at the Global Center for Health Innovation in Cleveland. Designed to promote the professional development of physicians and healthcare providers, the event will explore the current state of pediatric care and the cutting-edge medical advancements transforming the research and treatment of childhood diseases.

1 Jun 2015

Hip replacement procedure alleviates pain, improves function in young JIA patients

Hip replacement is often performed in patients with juvenile arthritis when their joints have been severely damaged by the disease.

25 Mar 2015

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints.

4 Feb 2015

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

After more than a decade-long wait, the revolutionary therapy that provided a new lease of life to millions of patients suffering from rheumatoid arthritis and other auto immune disorders globally will now be accessible to patients in India. Zydus Cadila becomes the first company anywhere in the world to launch the biosimilar of Adalimumab - the world's largest selling therapy.

9 Dec 2014